Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus sintilimab as neoadjuvant therapy for resectable MSI-H/dMMR colon cancer
CTR20231430Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310, sintilimab in colon cancer, sponsored by Innovent Biologics. Started Jun 2023; status: active.
02
Drugs
IBI310sintilimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on CTR20231430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231430.